Mnogofaktornoe upravlenie sakharnym diabetom 2 tipa: kakovy nashi segodnyashnie vozmozhnosti


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents data of published meta-analyses and systematic reviews on the effectiveness and safety of therapy with incretins, and the results of the combined measures of DM outcomes using different therapeutic approaches.

全文:

受限制的访问

作者简介

G. Galstyan

参考

  1. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76-9.
  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352(9131):837-53.
  3. Stratton I.M., Adler Al., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12.
  4. Patel A, MacMahon S., Chalmers J., et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
  5. Duckworth W., Abraira C., Moritz T., et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
  6. Gerstein H.C., Miller M.E., Byington R.P. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59.
  7. Buse J.B., Ginsberg H.N., Bakris G.L., et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30(1):162-72.
  8. Pi-Sunyer X., Blackburn G., Brancati F.L., et al; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30(6):1374-83.
  9. Goldenberg R.M. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. Canadian Journal of Diabetes 2011;35(5):518-27.
  10. Bennetti W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13.
  11. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812.
  12. ADA. Standards of medical care in diabetes, 2009. Diabetes Care 2009;32(Suppl. 1): 13-61.
  13. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists /American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
  14. DeFronzo R.A. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123:38-48.
  15. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
  16. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203.
  17. Schernthaner G., Barnett A.H., Betteridge D.J., et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53:1258-69.
  18. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124(1):3-18.
  19. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. AACE/ACE diabetes algorithm for glycemic control, 2009 [article on-line]. Available from https://www.aace.com/sites/default/files/ GlycemicControlAlgorithm.pdf. Accessed 17 November 2011.
  20. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
  21. Nauck M.A., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32:84-90.
  22. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
  23. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human GLP-1 analogue liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
  24. Russell-Jones D., Vaag A., Schmitz O., et al. On behalf of the LEAD-5 met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009;52:2046-55.
  25. Buse J.B., Rosenstock J., Sesti G., et al; for the LEAD Study Group. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009;374:39-47.
  26. Pratley R.E., Nauck M., Bailey T., et al; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
  27. Nauck M.A., Vaag A., Colagiuri S., et al. HbA1c reduction with liraglutide in type 2 diabetes patients is associated with initial HbA1c levels. International Diabetes Federation - 20th World Diabetes Congress 2009;1400.
  28. Henry R.R., Buse J.B., Sesti G., et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1c: a meta-analysis of the liraglutide development program. Endocr Pract 2011;17(6):906-13.
  29. Holst J.J., Nauck M., Brett J., Falahati A., Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009;52(1) :288.
  30. Buse J.B., Sesti G., Schmidt W.E., et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes care, 2010; 33(6):1300-303
  31. Pratley R.E. et al. Diabetes 2011: 60(1):1119-P.
  32. Fakhoury W.K., Lereun C., Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57.
  33. Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clinical diabetes 2012;30(1):3-12.
  34. Meneghini L.F., Orozco-Beltran D., Khunti K., Caputo S., et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011;96(11):3337-53.
  35. Ismail M.H. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. Am J MedSci 2011;341:485-92.
  36. Vilsb ll T., Christensen M., Junker A.E., et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and metaanalyses of randomised controlled trials. BMJ 2012;344:d7771 doi: 10.1136/bmj.d7771 (Published 11 January 2012).
  37. Gilbert M.P., Pratley R.E. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. The American Journal of Medicine 2009;122(6A):11-24.
  38. Zinman B., Colagiuri S., Madsbad S., et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: meta-analysis of six phase 3 trials. Diabetes 2010;59(Suppl. 1): A495 (1894-P).
  39. Karagiannis T., Paschos P., Paletas K., et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 doi: 10.1136/bmj.e1369 (Published 12 March 2012).
  40. Repas T. Next generetion GLP-1 therapy: an introduction to liraglutide. Postgraduate Madicine 2011;123(5):239-47.
  41. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patient with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;35(9118): 1755-62.
  42. Patel A. ADVANCE Collaborative Group, MacMahon S, et al. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomice controlled trial. Lancet 2007;370(9590):829-40.
  43. Fonseca V., Madsbad S., Falahati A., et al. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: a metaanalysis of six clinical trials (LEAD). Diabetes 2009;58(1):A146.
  44. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? The American Journal of Medicine 2011; 124:19-34.
  45. Zinman B., Schmidt W.E., Moses A., et al. Achieving a clinically relevant composite outcome of an HbA1c of №7 % without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes, Obesity and Metabolism 2011;doi:10.1111/ j.1463-1326.2011.01493.x.
  46. Zinman B., Buse J,, Falahati A., et al. Liraglutide more effectively achieves a composite endpoint for A1C, SBP and weight change than other diabetes therapies. Diabetes 2009;58(Suppl. 1):A143.
  47. Garber A. Incretin effects on b-cell function, replication, and mass. Diabetes care 2011;34(2):258-63.
  48. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G.L. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32(5):834-38.
  49. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск) / Под ред. И.И. Дедова, М.В. Шестаковой. М., 2011: 116 с.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##